爱美客 (300896)

1. Key Indicators

• Total Shares(W): 30259.21
• Circulating A-Shares(W): 20859.16
• Earnings Per Share(RMB): 3.6300
• Net Assets Per Share(RMB): 24.4246
• Operating Revenue(W RMB): 186496.60
• Total Profit(W RMB): 128028.11
• Net Profit Attributable to Parent(W RMB): 109326.35
• Net Profit Growth Rate(%): -31.05
• Weighted Return on Equity(%): 14.1800
• Operating Cash Flow Per Share(RMB): 3.5450
• Undistributed Profit Per Share(RMB): 13.0923
• Capital Reserve Per Share(RMB): 11.2042

---

2. Main Business

The main business covers:

• Research, development and transformation of biomedical materials and biopharmaceutical products.

---

3. Company Basic Information

• Company Name: Imeik Technology Development Co., Ltd.
• Listing Date: 2020-09-28
• Industry: Pharmaceuticals & Healthcare - Medical Aesthetics
• Address: 21F, Tower C, Shimao Building, No. A92 Jianguo Road, Chaoyang District, Beijing
• Website: www.imeik.net
• Company Profile: The company is an innovative leader in the field of biomedical soft tissue repair materials in China. Based on the research, development and transformation of biomedical materials, and committed to the development of recombinant proteins and polypeptides and other biopharmaceuticals, the company has successfully industrialized injectable hyaluronic acid series products and poly-p-dioxanone facial implant threads, and has established product technology transformation platforms for biomedical materials such as medical chitosan and polylactic acid. Product clinical applications cover medical aesthetics, surgical repair and metabolic disease treatment. The company is the first domestic enterprise to obtain the National Medical Products Administration (NMPA) approval for an injectable hyaluronic acid medical device product registration certificate for facial soft tissue repair. As of the end of the reporting period, the company had five NMPA-approved Class III injectable hyaluronic acid series products, making it the company with the most approved similar products by the NMPA. The company's five products differ in formulation components, injection sites, and injection experience, meeting consumer demand in multiple market segments. In addition, the company obtained the Class III medical device registration certificate for poly-p-dioxanone facial implant threads in May 2019, which is the first facial implant thread product approved by the NMPA.

---

4. Top 10 Circulating Shareholders

Rank	Institution Name	Institution Type	Shares Held (W)	Percentage Held (%)
1	Xiamen Zhixin Junxing Investment Partnership (Limited Partnership)	General Legal Person	1942.81	9.31
2	Xiamen Danrui Investment Partnership (Limited Partnership)	General Legal Person	1467.90	7.04
3	Xiamen Keshishang Investment Partnership (Limited Partnership)	General Legal Person	1295.21	6.21
4	Hong Kong Securities Clearing Company Ltd.	Northbound Funds	682.95	3.27
5	HuaBao CSI Healthcare Sector Index ETF	Fund	425.89	2.04
6	E Fund ChiNext Index ETF	Fund	293.34	1.41
7	Huatai-PineBridge CSI 300 Index ETF	Fund	267.73	1.28
8	China Merchants Guozheng Bio-medicine Index Securities Investment Fund (LOF) Class A	Fund	196.03	0.94
9	Yongying CSI Total Return Medical Devices ETF	Fund	93.17	0.45
10	Tianhong Guozheng Bio-medicine ETF	Fund	68.82	0.33

---

5. Concept Sectors

• Medical Aesthetics Concept
• Weight Loss Drugs
• Synthetic Biology
• Margin Trading & Securities Lending
• High-Performance Stocks
• Industry Leader
• Hundred-Yuan Stocks
• MSCI Constituent
• Specialized, Refined, Distinctive, and Innovative SMEs
• Below Issue Price
• Non-Cyclical Stocks
• Zhongchuang 100
• ChiNext Index
• Mid-Cap Growth
• SZSE 100
• SZSE 300
• Technology 100
• SZSE Governance
• Consumption 100
• SZSE Governance Index
• SZSE Growth Index
• SZSE Growth
• CSI 300
• ChiNext 300
• CSI 200
• 300 Non-Cyclical
• SZSE Innovation
• ChiNext Innovation
• ChiNext Large Cap
• ChiNext Quality
• ChiNext Healthcare
• Innovation 100
• 300 ESG

---

Remarks

• Data update date: 2026-01-01
• Data source: Public Market Information